ORPP logo
Image from Google Jackets

Lipid Nanocarriers for Drug Targeting.

By: Material type: TextTextSeries: Pharmaceutical Nanotechnology SeriesPublisher: San Diego : Elsevier Science & Technology Books, 2018Copyright date: ©2018Edition: 1st edDescription: 1 online resource (676 pages)Content type:
  • text
Media type:
  • computer
Carrier type:
  • online resource
ISBN:
  • 9780128136881
Subject(s): Genre/Form: Additional physical formats: Print version:: Lipid Nanocarriers for Drug TargetingDDC classification:
  • 615.19
LOC classification:
  • RM301.63 .L575 2018
Online resources:
Contents:
Front Cover -- Lipid Nanocarriers for Drug Targeting -- Copyright Page -- Contents -- List of Contributors -- Series Preface: Pharmaceutical Nanotechnology -- Preface -- 1 Lipid nanocarriers -- 1.1 Introduction to Lipid Nanocarriers -- 1.1.1 Classification: (Mehanna et al., 2012) -- 1.2 Liposome -- 1.2.1 Introduction -- 1.2.2 Classification Of Liposomes x -- 1.2.3 Composition -- 1.2.4 Method of Preparation of Liposomes -- 1.2.4.1 Hydration method (Bangham Method) -- 1.2.4.2 Ethanol injection method -- 1.2.4.3 Ether injection -- 1.2.4.4 Sonication -- 1.2.4.5 Microemulsification method -- 1.2.5 Characterization -- 1.3 Ethosomes -- 1.3.1 Introduction -- 1.3.2 Composition -- 1.3.3 Method of Preparation of Ethosomes -- 1.3.3.1 Cold method -- 1.3.3.2 Hot method -- 1.3.3.3 Classic mechanical dispersion method -- 1.3.3.4 Classic method -- 1.3.4 Characterization -- 1.4 Transfersomes -- 1.4.1 Introduction -- 1.4.2 Composition -- 1.4.3 Method of Preparation of Transfersomes -- 1.4.3.1 Vortexing-sonication method -- 1.4.3.2 Rotary evaporation-sonication method -- 1.4.3.3 Modified hand-shaking method -- 1.4.4 Characterization -- 1.5 Solid Lipid Nanoparticles -- 1.5.1 Introduction -- 1.5.2 Classification -- 1.5.2.1 Solid lipid nanoparticle Type I or homogenous matrix model -- 1.5.2.2 Solid lipid nanoparticles, Type II or drug-enriched shell model -- 1.5.2.3 Solid lipid nanoparticles, Type III or drug-enriched CORE model -- 1.5.3 Composition -- 1.5.4 Method of Preparation of Solid Lipid Nanoparticle -- 1.5.4.1 High pressure homogenization (HPH) -- 1.5.4.1.1 Hot homogenization -- 1.5.4.1.2 Cold homogenization -- 1.5.4.2 Ultrasonication/high speed homogenization -- 1.5.4.3 Solvent evaporation -- 1.5.4.4 Solvent emulsification-diffusion method -- 1.5.4.5 Supercritical fluid method -- 1.5.4.6 Microemulsion-based method -- 1.5.4.7 Spray drying method.
1.5.4.8 Double emulsion method -- 1.5.4.9 Precipitation method -- 1.5.4.10 Film-ultrasound dispersion -- 1.5.5 Characterization -- 1.6 Nanostructured Lipid Carriers (NLC) -- 1.6.1 Introduction -- 1.6.2 Classification -- 1.6.2.1 Imperfect type nanostructured lipid carriers -- 1.6.2.2 Multiple types nanostructured lipid carriers -- 1.6.2.3 Amorphous type nanostructured lipid carriers -- 1.6.3 Composition -- 1.6.4 Methods for Preparation Nanostructured Lipid Carriers -- 1.6.4.1 Hot homogenization -- 1.6.4.2 Cold homogenization -- 1.6.4.3 Microemulsion -- 1.6.5 Chacterization -- 1.7 Lipid Drug Conjugates (LDC) -- 1.7.1 Introduction -- 1.7.2 Composition -- 1.7.3 Method of Preparation of Lipid Drugs Conjugates -- 1.7.3.1 High pressure homogenization -- 1.7.3.1.1 Hot homogenization -- 1.7.3.1.2 Cold homogenization -- 1.7.3.2 Ultrasonication/high speed homogenization -- 1.7.3.3 Solvent evaporation method -- 1.7.3.4 Solvent emulsification-diffusion method -- 1.7.3.5 Supercritical fluid method -- 1.7.3.6 Microemulsion-based method -- 1.7.3.7 Spray drying method -- 1.7.4 Characterization -- 1.8 Marketed or Commercially Available Nanolipid Products -- 1.9 Applications of Various Lipid Nanocarriers -- 1.9.1 Applications of Liposomes -- 1.9.1.1 Liposomes for gene delivery -- 1.9.1.2 Liposome for targeted delivery -- 1.9.1.3 Liposomes in cosmetics -- 1.9.1.4 Liposomes in ocular delivery -- 1.9.1.5 Liposomes in some other fields -- 1.9.2 Applications of Solid Lipid Nanoparticles -- 1.9.2.1 Solid lipid nanoparticles for parenteral application -- 1.9.2.2 Solid lipid nanoparticles for nasal application -- 1.9.2.3 Solid lipid nanoparticles for respiratory application -- 1.9.2.4 Solid lipid nanoparticles for ocular application -- 1.9.2.5 Solid lipid nanoparticles for rectal application -- 1.9.2.6 Solid lipid nanoparticles for topical application.
1.9.2.7 Solid lipid nanoparticles in cancer chemotherapy -- 1.9.2.8 Oral solid lipid nanoparticles in antitubercular chemotherapy -- 1.9.2.9 Solid lipid nanoparticles for potential agriculture application -- 1.9.2.10 Solid lipid nanoparticles applied to the treatment of malaria -- 1.9.2.11 Solid lipid nanoparticles applications for improved delivery of antiretroviral drugs to the brain -- 1.9.2.12 Solid lipid nanoparticles as gene vector carrier -- 1.9.3 Application of Nanostructured Lipid Carriers -- 1.9.3.1 Parenteral injection -- 1.9.3.2 Nanostructured lipid carriers in brain targeting -- 1.9.3.3 Nanostructured lipid carriers in antihepatotoxic injection -- 1.9.3.4 Nanostructured lipid carriers in Analgesia -- 1.9.3.5 Nanostructured lipid carriers in antiinflammatory action -- 1.9.3.6 Nanostructured lipid carriers in topical delivery -- 1.9.3.7 Nanostructured lipid carriers in oral delivery -- 1.9.3.8 Nanostructured lipid carriers in ocular delivery -- 1.9.4 Application of Lipid Drug Conjugates -- 1.10 Conclusion -- 1.11 Future Prospects -- References -- Further Reading -- 2 Lipid nanoparticulate systems: Modern versatile drug carriers -- 2.1 Introduction -- 2.1.1 History and Development of Lipid-Based Drug Delivery Systems -- 2.2 Lipid Nanoparticulate Systems: Types and Definitions -- 2.3 Methods of Preparation -- 2.3.1 High Energy Input Methods -- 2.3.1.1 High pressure homogenization technique -- 2.3.1.2 High shear homogenization technique -- 2.3.1.3 Ultrasonication technique -- 2.3.1.4 Electro-spray technique -- 2.3.2 Low Energy Input Methods -- 2.3.2.1 Nanoparticle Precipitation from Homogeneous Systems -- 2.3.2.2 Solvent-based methods -- 2.3.3 Miscellaneous Methods -- 2.3.3.1 Film ultrasonication dispersion technique -- 2.3.4 Postmanufacturing Processing of Nanoparticles -- 2.3.4.1 Drying.
2.3.4.2 Sterilization and antimicrobial preservation -- 2.3.4.3 Stabilization -- 2.4 Structure and Morphology of Lipid-Based Nanoparticles -- 2.4.1 Structure of Solid Lipid Nanoparticles -- 2.4.1.1 Drug-enriched shell model -- 2.4.1.2 Drug-enriched core model -- 2.4.1.3 Solid solution model -- 2.4.2 Structure of Nanostructured Lipid Carriers -- 2.4.2.1 Nanostructured lipid carrier type I or imperfect crystal type -- 2.4.2.2 Nanostructured lipid carrier type II or multiple oil/fat/water (O/F/W) type -- 2.4.2.3 Nanostructured lipid carrier type III or structureless/amorphous type -- 2.5 Composition of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers -- 2.5.1 Lipids -- 2.5.1.1 Factors affecting selection of lipids -- 2.5.2 Surfactants/Emulsifiers -- 2.5.3 Cosurfactants -- 2.5.4 Other Ingredients -- 2.6 Characterization of Lipid Nanoparticles -- 2.6.1 Particle Size and Size Distribution -- 2.6.1.1 Photon correlation spectroscopy/dynamic light scattering/quasi-elastic light scattering -- 2.6.1.2 Laser diffraction -- 2.6.1.3 Field-flow fractionation method -- 2.6.1.4 Coulter counter method -- 2.6.2 Particle Shape, Morphology, and Ultrastructure -- 2.6.2.1 Scanning electron microscopy -- 2.6.2.2 Transmission electron microscopy -- 2.6.2.3 Atomic force microscopy -- 2.6.3 Zeta Potential/Surface Charge -- 2.6.4 Drug Loading -- 2.6.5 Entrapment Efficiency -- 2.6.6 Viscosity and Rheological Properties -- 2.6.7 Lipid Characterization (Determination of Melting Point, Crystallinity and Polymorphism) -- 2.6.7.1 Differential scanning calorimetry -- 2.6.7.2 Powder X-ray diffraction -- 2.6.7.3 Small angle X-ray scattering -- 2.6.8 Coexistence of Additional Colloidal Structures and Interaction With Incorporated Drugs -- 2.6.8.1 Nuclear magnetic resonance -- 2.6.8.2 Electron spin/paramagnetic resonance -- 2.6.9 In vitro Drug Release/Dissolution.
2.7 Stability Aspects of Solid Lipid Nanoparticles/Nanostructured Lipid Carriers -- 2.7.1 Stabilization Mechanisms and Optimization of Stability -- 2.7.1.1 Physical stability -- 2.7.1.2 Chemical stability -- 2.7.1.3 Biological stability -- 2.7.1.4 Storage stability -- 2.8 Safety and Toxicological Aspects -- 2.8.1 Physicochemical Characterization -- 2.8.2 In vitro Cell Culture Techniques -- 2.9 Applications of Solid Lipid Nanoparticles/Nanostructured Lipid Carriers by Different Routes of Administration -- 2.9.1 Parenteral Delivery -- 2.9.1.1 Tumor targeting -- 2.9.1.2 Liver targeting -- 2.9.1.3 For imaging -- 2.9.1.4 Brain targeting -- 2.9.1.5 For treatment of cardiovascular diseases -- 2.9.1.6 For treatment of parasitic diseases -- 2.9.1.7 For treatment of rheumatoid arthritis -- 2.9.2 Topical, Dermal, Transdermal, and Mucosal Delivery -- 2.9.3 Cosmetic and Cosmeceutical Delivery -- 2.9.4 Oral Delivery -- 2.9.5 Ocular Drug Delivery -- 2.9.6 Pulmonary Delivery -- 2.9.7 Gene, Protein, and Peptide Delivery -- 2.9.8 As Vaccine Adjuvant -- 2.9.9 Phytochemical and Nutraceutical Delivery -- 2.10 Conclusions -- Acknowledgments -- References -- Further Reading -- 3 Nanotechnology in phytotherapy: Current challenges of lipid-based nanocarriers for the delivery of natural products -- 3.1 Introduction -- 3.1.1 Phytotherapic Technology -- 3.1.2 Chemical Characterization of Herbal Drug -- 3.2 Lipid Nanocarriers Containing Natural Products -- 3.2.1 Challenges in Development -- 3.2.2 Micelles -- 3.2.3 Submicron Emulsions (Micro- and Nanoemulsions) -- 3.2.4 Liposomes -- 3.2.5 Solid Lipid Nanoparticles -- 3.3 Outlook -- References -- Further Reading -- 4 Innovative vesicles for dermal and transdermal drug delivery -- 4.1 Introduction -- 4.2 The Skin and Drug Penetration Routes -- 4.3 Liposomes -- 4.4 Ethosomes -- 4.5 Transferosomes -- 4.6 Niosomes -- 4.7 Conclusion.
References.
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
No physical items for this record

Front Cover -- Lipid Nanocarriers for Drug Targeting -- Copyright Page -- Contents -- List of Contributors -- Series Preface: Pharmaceutical Nanotechnology -- Preface -- 1 Lipid nanocarriers -- 1.1 Introduction to Lipid Nanocarriers -- 1.1.1 Classification: (Mehanna et al., 2012) -- 1.2 Liposome -- 1.2.1 Introduction -- 1.2.2 Classification Of Liposomes x -- 1.2.3 Composition -- 1.2.4 Method of Preparation of Liposomes -- 1.2.4.1 Hydration method (Bangham Method) -- 1.2.4.2 Ethanol injection method -- 1.2.4.3 Ether injection -- 1.2.4.4 Sonication -- 1.2.4.5 Microemulsification method -- 1.2.5 Characterization -- 1.3 Ethosomes -- 1.3.1 Introduction -- 1.3.2 Composition -- 1.3.3 Method of Preparation of Ethosomes -- 1.3.3.1 Cold method -- 1.3.3.2 Hot method -- 1.3.3.3 Classic mechanical dispersion method -- 1.3.3.4 Classic method -- 1.3.4 Characterization -- 1.4 Transfersomes -- 1.4.1 Introduction -- 1.4.2 Composition -- 1.4.3 Method of Preparation of Transfersomes -- 1.4.3.1 Vortexing-sonication method -- 1.4.3.2 Rotary evaporation-sonication method -- 1.4.3.3 Modified hand-shaking method -- 1.4.4 Characterization -- 1.5 Solid Lipid Nanoparticles -- 1.5.1 Introduction -- 1.5.2 Classification -- 1.5.2.1 Solid lipid nanoparticle Type I or homogenous matrix model -- 1.5.2.2 Solid lipid nanoparticles, Type II or drug-enriched shell model -- 1.5.2.3 Solid lipid nanoparticles, Type III or drug-enriched CORE model -- 1.5.3 Composition -- 1.5.4 Method of Preparation of Solid Lipid Nanoparticle -- 1.5.4.1 High pressure homogenization (HPH) -- 1.5.4.1.1 Hot homogenization -- 1.5.4.1.2 Cold homogenization -- 1.5.4.2 Ultrasonication/high speed homogenization -- 1.5.4.3 Solvent evaporation -- 1.5.4.4 Solvent emulsification-diffusion method -- 1.5.4.5 Supercritical fluid method -- 1.5.4.6 Microemulsion-based method -- 1.5.4.7 Spray drying method.

1.5.4.8 Double emulsion method -- 1.5.4.9 Precipitation method -- 1.5.4.10 Film-ultrasound dispersion -- 1.5.5 Characterization -- 1.6 Nanostructured Lipid Carriers (NLC) -- 1.6.1 Introduction -- 1.6.2 Classification -- 1.6.2.1 Imperfect type nanostructured lipid carriers -- 1.6.2.2 Multiple types nanostructured lipid carriers -- 1.6.2.3 Amorphous type nanostructured lipid carriers -- 1.6.3 Composition -- 1.6.4 Methods for Preparation Nanostructured Lipid Carriers -- 1.6.4.1 Hot homogenization -- 1.6.4.2 Cold homogenization -- 1.6.4.3 Microemulsion -- 1.6.5 Chacterization -- 1.7 Lipid Drug Conjugates (LDC) -- 1.7.1 Introduction -- 1.7.2 Composition -- 1.7.3 Method of Preparation of Lipid Drugs Conjugates -- 1.7.3.1 High pressure homogenization -- 1.7.3.1.1 Hot homogenization -- 1.7.3.1.2 Cold homogenization -- 1.7.3.2 Ultrasonication/high speed homogenization -- 1.7.3.3 Solvent evaporation method -- 1.7.3.4 Solvent emulsification-diffusion method -- 1.7.3.5 Supercritical fluid method -- 1.7.3.6 Microemulsion-based method -- 1.7.3.7 Spray drying method -- 1.7.4 Characterization -- 1.8 Marketed or Commercially Available Nanolipid Products -- 1.9 Applications of Various Lipid Nanocarriers -- 1.9.1 Applications of Liposomes -- 1.9.1.1 Liposomes for gene delivery -- 1.9.1.2 Liposome for targeted delivery -- 1.9.1.3 Liposomes in cosmetics -- 1.9.1.4 Liposomes in ocular delivery -- 1.9.1.5 Liposomes in some other fields -- 1.9.2 Applications of Solid Lipid Nanoparticles -- 1.9.2.1 Solid lipid nanoparticles for parenteral application -- 1.9.2.2 Solid lipid nanoparticles for nasal application -- 1.9.2.3 Solid lipid nanoparticles for respiratory application -- 1.9.2.4 Solid lipid nanoparticles for ocular application -- 1.9.2.5 Solid lipid nanoparticles for rectal application -- 1.9.2.6 Solid lipid nanoparticles for topical application.

1.9.2.7 Solid lipid nanoparticles in cancer chemotherapy -- 1.9.2.8 Oral solid lipid nanoparticles in antitubercular chemotherapy -- 1.9.2.9 Solid lipid nanoparticles for potential agriculture application -- 1.9.2.10 Solid lipid nanoparticles applied to the treatment of malaria -- 1.9.2.11 Solid lipid nanoparticles applications for improved delivery of antiretroviral drugs to the brain -- 1.9.2.12 Solid lipid nanoparticles as gene vector carrier -- 1.9.3 Application of Nanostructured Lipid Carriers -- 1.9.3.1 Parenteral injection -- 1.9.3.2 Nanostructured lipid carriers in brain targeting -- 1.9.3.3 Nanostructured lipid carriers in antihepatotoxic injection -- 1.9.3.4 Nanostructured lipid carriers in Analgesia -- 1.9.3.5 Nanostructured lipid carriers in antiinflammatory action -- 1.9.3.6 Nanostructured lipid carriers in topical delivery -- 1.9.3.7 Nanostructured lipid carriers in oral delivery -- 1.9.3.8 Nanostructured lipid carriers in ocular delivery -- 1.9.4 Application of Lipid Drug Conjugates -- 1.10 Conclusion -- 1.11 Future Prospects -- References -- Further Reading -- 2 Lipid nanoparticulate systems: Modern versatile drug carriers -- 2.1 Introduction -- 2.1.1 History and Development of Lipid-Based Drug Delivery Systems -- 2.2 Lipid Nanoparticulate Systems: Types and Definitions -- 2.3 Methods of Preparation -- 2.3.1 High Energy Input Methods -- 2.3.1.1 High pressure homogenization technique -- 2.3.1.2 High shear homogenization technique -- 2.3.1.3 Ultrasonication technique -- 2.3.1.4 Electro-spray technique -- 2.3.2 Low Energy Input Methods -- 2.3.2.1 Nanoparticle Precipitation from Homogeneous Systems -- 2.3.2.2 Solvent-based methods -- 2.3.3 Miscellaneous Methods -- 2.3.3.1 Film ultrasonication dispersion technique -- 2.3.4 Postmanufacturing Processing of Nanoparticles -- 2.3.4.1 Drying.

2.3.4.2 Sterilization and antimicrobial preservation -- 2.3.4.3 Stabilization -- 2.4 Structure and Morphology of Lipid-Based Nanoparticles -- 2.4.1 Structure of Solid Lipid Nanoparticles -- 2.4.1.1 Drug-enriched shell model -- 2.4.1.2 Drug-enriched core model -- 2.4.1.3 Solid solution model -- 2.4.2 Structure of Nanostructured Lipid Carriers -- 2.4.2.1 Nanostructured lipid carrier type I or imperfect crystal type -- 2.4.2.2 Nanostructured lipid carrier type II or multiple oil/fat/water (O/F/W) type -- 2.4.2.3 Nanostructured lipid carrier type III or structureless/amorphous type -- 2.5 Composition of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers -- 2.5.1 Lipids -- 2.5.1.1 Factors affecting selection of lipids -- 2.5.2 Surfactants/Emulsifiers -- 2.5.3 Cosurfactants -- 2.5.4 Other Ingredients -- 2.6 Characterization of Lipid Nanoparticles -- 2.6.1 Particle Size and Size Distribution -- 2.6.1.1 Photon correlation spectroscopy/dynamic light scattering/quasi-elastic light scattering -- 2.6.1.2 Laser diffraction -- 2.6.1.3 Field-flow fractionation method -- 2.6.1.4 Coulter counter method -- 2.6.2 Particle Shape, Morphology, and Ultrastructure -- 2.6.2.1 Scanning electron microscopy -- 2.6.2.2 Transmission electron microscopy -- 2.6.2.3 Atomic force microscopy -- 2.6.3 Zeta Potential/Surface Charge -- 2.6.4 Drug Loading -- 2.6.5 Entrapment Efficiency -- 2.6.6 Viscosity and Rheological Properties -- 2.6.7 Lipid Characterization (Determination of Melting Point, Crystallinity and Polymorphism) -- 2.6.7.1 Differential scanning calorimetry -- 2.6.7.2 Powder X-ray diffraction -- 2.6.7.3 Small angle X-ray scattering -- 2.6.8 Coexistence of Additional Colloidal Structures and Interaction With Incorporated Drugs -- 2.6.8.1 Nuclear magnetic resonance -- 2.6.8.2 Electron spin/paramagnetic resonance -- 2.6.9 In vitro Drug Release/Dissolution.

2.7 Stability Aspects of Solid Lipid Nanoparticles/Nanostructured Lipid Carriers -- 2.7.1 Stabilization Mechanisms and Optimization of Stability -- 2.7.1.1 Physical stability -- 2.7.1.2 Chemical stability -- 2.7.1.3 Biological stability -- 2.7.1.4 Storage stability -- 2.8 Safety and Toxicological Aspects -- 2.8.1 Physicochemical Characterization -- 2.8.2 In vitro Cell Culture Techniques -- 2.9 Applications of Solid Lipid Nanoparticles/Nanostructured Lipid Carriers by Different Routes of Administration -- 2.9.1 Parenteral Delivery -- 2.9.1.1 Tumor targeting -- 2.9.1.2 Liver targeting -- 2.9.1.3 For imaging -- 2.9.1.4 Brain targeting -- 2.9.1.5 For treatment of cardiovascular diseases -- 2.9.1.6 For treatment of parasitic diseases -- 2.9.1.7 For treatment of rheumatoid arthritis -- 2.9.2 Topical, Dermal, Transdermal, and Mucosal Delivery -- 2.9.3 Cosmetic and Cosmeceutical Delivery -- 2.9.4 Oral Delivery -- 2.9.5 Ocular Drug Delivery -- 2.9.6 Pulmonary Delivery -- 2.9.7 Gene, Protein, and Peptide Delivery -- 2.9.8 As Vaccine Adjuvant -- 2.9.9 Phytochemical and Nutraceutical Delivery -- 2.10 Conclusions -- Acknowledgments -- References -- Further Reading -- 3 Nanotechnology in phytotherapy: Current challenges of lipid-based nanocarriers for the delivery of natural products -- 3.1 Introduction -- 3.1.1 Phytotherapic Technology -- 3.1.2 Chemical Characterization of Herbal Drug -- 3.2 Lipid Nanocarriers Containing Natural Products -- 3.2.1 Challenges in Development -- 3.2.2 Micelles -- 3.2.3 Submicron Emulsions (Micro- and Nanoemulsions) -- 3.2.4 Liposomes -- 3.2.5 Solid Lipid Nanoparticles -- 3.3 Outlook -- References -- Further Reading -- 4 Innovative vesicles for dermal and transdermal drug delivery -- 4.1 Introduction -- 4.2 The Skin and Drug Penetration Routes -- 4.3 Liposomes -- 4.4 Ethosomes -- 4.5 Transferosomes -- 4.6 Niosomes -- 4.7 Conclusion.

References.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.

There are no comments on this title.

to post a comment.

© 2024 Resource Centre. All rights reserved.